Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Servicio Andaluz De Salud has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 2 distinct art units. This indicates a moderately diverse prosecution landscape for the company's current filings. The involvement of 3 distinct examiners for 3 pending actions ensures that the company's progress is not tied to a single individual's review, providing a more varied set of opportunities for allowance within the Biotechnology & Pharmaceuticals sector.
LEXUS MARC TATGE is the busiest examiner, currently handling 1 busiest examiner pending action. Although there are 3 pending office actions in total, the workload is distributed such that the busiest examiner only manages 1 of them. The presence of 2 distinct art units suggests that the company is navigating multiple technical sub-sectors. This requires the legal team to manage the specific requirements of 2 distinct art units while addressing the 3 pending actions across the 3 distinct examiners currently assigned to the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TATGE, LEXUS MARC | 1 | 50.0% | +100.0% |
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
| ZEMAN, ROBERT A | 1 | 54.3% | +27.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704750 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENT | TATGE, LEXUS MARC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17611460 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENTS | MARVICH, MARIA | 84d overdue |
| 18704750 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENT | TATGE, LEXUS MARC | — |
| 17488545 | VACCINE AGAINST ACINETOBACTER BAUMANNII BASED ON CELLULAR COMPONENTS DEFICIENT IN LIPOPOLYSACCHARIDE | ZEMAN, ROBERT A | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704750 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENT | TATGE, LEXUS MARC | — | §101§103§112DP | Non-Final OA | — | Pending | Apr 25, 2024 |
| 17611460 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENTS | MARVICH, MARIA | 1634 | §112DP | Non-Final OA | 84d overdue | Pending | Nov 15, 2021 |
| 17488545 | VACCINE AGAINST ACINETOBACTER BAUMANNII BASED ON CELLULAR COMPONENTS DEFICIENT IN LIPOPOLYSACCHARIDE | ZEMAN, ROBERT A | 1645 | §103 | Non-Final OA | — | Pending | Sep 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial